Homepage > Company > Media > Pharma News > 2019 > Johnson & Johnson to test experimental HIV vaccine in U.S., Europe

Johnson & Johnson to test experimental HIV vaccine in U.S., Europe

(Reuters) - Johnson & Johnson said on Friday it plans to conduct a late-stage study of its investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.

The drugmaker already has a mid-stage HIV vaccine study underway in five southern African countries.

There are currently no vaccines for HIV, a virus that weakens the body’s immune system.

JULY 12, 2019

https://www.reuters.com/

Read also

Alembic Pharma rises on USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals advanced 1.10% to Rs 918.15 after the company received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (A...

GSK to spend $2bn on Phase III liver disease drug acquisition

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals’ efimosfermin, a drug ready to hit Phase III trials for the treatment of...

Amneal Receives U.S. FDA Approval for Brekiya®

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Preclinical + European Hematology Association 2025 Congress

Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA...